NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name (Ascending) | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00517-0420-01 | 00517-0420 | ESTRADIOL VALERATE | ESTRADIOL VALERATE | 20.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | March 1, 2020 | In Use | ||
00517-0440-01 | 00517-0440 | ESTRADIOL VALERATE | ESTRADIOL VALERATE | 40.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | March 1, 2020 | In Use | ||
00015-3404-20 | 00015-3404 | etoposide phosphate | ETOPOPHOS | 100.0 mg/1 | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | June 1, 2009 | April 30, 2021 | No Longer Used |
70377-0010-22 | 70377-0010 | Everolimus | EVEROLIMUS | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct. 1, 2021 | In Use | |
70377-0010-11 | 70377-0010 | Everolimus | EVEROLIMUS | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 8, 2023 | In Use | |
70377-0011-22 | 70377-0011 | Everolimus | EVEROLIMUS | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct. 1, 2021 | In Use | |
70377-0011-11 | 70377-0011 | Everolimus | EVEROLIMUS | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 8, 2023 | In Use | |
70377-0012-22 | 70377-0012 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct. 1, 2021 | In Use | |
70377-0012-11 | 70377-0012 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 8, 2023 | In Use | |
70377-0013-22 | 70377-0013 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct. 1, 2021 | In Use | |
70377-0013-11 | 70377-0013 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 8, 2023 | In Use | |
69097-0316-02 | 69097-0316 | exemestane | EXEMESTANE | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | April 27, 2018 | In Use | ||
63020-0040-12 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sept. 15, 2021 | In Use | |
63020-0040-90 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sept. 15, 2021 | In Use | |
00187-3204-47 | 00187-3204 | Fluorouracil | Efudex | 2.0 g/40g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | July 29, 1970 | In Use | |
54868-0951-00 | 54868-0951 | Fluorouracil | Efudex | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | July 29, 1970 | Sept. 30, 2011 | No Longer Used | |
00024-0222-05 | 00024-0222 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan. 23, 2002 | May 31, 2016 | No Longer Used | ||
00024-0605-45 | 00024-0605 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan. 23, 2002 | May 31, 2016 | No Longer Used | ||
00024-0610-30 | 00024-0610 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan. 23, 2002 | May 31, 2016 | No Longer Used | ||
00024-0793-75 | 00024-0793 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan. 23, 2002 | May 31, 2016 | No Longer Used | ||
62935-0223-05 | 62935-0223 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug. 26, 2002 | In Use | |||
62935-0453-45 | 62935-0453 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan. 7, 2005 | In Use | |||
62935-0753-75 | 62935-0753 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | May 15, 2002 | In Use | |||
62935-0452-45 | 62935-0452 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan. 23, 2002 | April 26, 2019 | No Longer Used | ||
62935-0222-05 | 62935-0222 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug. 26, 2002 | April 26, 2019 | In Use | ||
62935-0302-30 | 62935-0302 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Feb. 26, 2003 | April 26, 2019 | In Use | ||
62935-0752-75 | 62935-0752 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | May 15, 2002 | April 26, 2019 | In Use | ||
62935-0461-50 | 62935-0461 | Leuprolide acetate | Eligard | 45.0 mg/.375mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | March 6, 2023 | In Use | ||
62935-0227-10 | 62935-0227 | Leuprolide acetate | Eligard | 22.5 mg/.375mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov. 27, 2023 | In Use | ||
62935-0306-40 | 62935-0306 | Leuprolide acetate | Eligard | 30.0 mg/.5mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan. 11, 2024 | In Use | ||
62935-0756-80 | 62935-0756 | Leuprolide acetate | Eligard | 7.5 mg/.25mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov. 1, 2023 | In Use | ||
62935-0303-30 | 62935-0303 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Feb. 26, 2003 | In Use | |||
00024-5150-10 | 00024-5150 | Rasburicase | Elitek | Ancillary Therapy | Metabolic Agent | Enzyme | July 12, 2002 | In Use | |||
00024-5151-75 | 00024-5151 | Rasburicase | Elitek | Ancillary Therapy | Metabolic Agent | Enzyme | June 1, 2006 | In Use | |||
00009-5091-01 | 00009-5091 | Epirubicin Hydrochloride | Ellence | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 15, 1999 | In Use | |
00009-5093-01 | 00009-5093 | Epirubicin Hydrochloride | Ellence | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 15, 1999 | In Use | |
12516-0592-04 | 12516-0592 | Oxaliplatin | Eloxatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | July 22, 2009 | July 22, 2009 | In Use |
00024-0591-20 | 00024-0591 | Oxaliplatin | Eloxatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 2, 2006 | Oct. 30, 2018 | No Longer Used |
00024-0590-10 | 00024-0590 | Oxaliplatin | Eloxatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 2, 2006 | Dec. 1, 2018 | No Longer Used |
63539-0252-02 | 63539-0252 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug. 15, 2023 | In Use | |
00069-4494-02 | 00069-4494 | Elranatamab-bcmm | Elrexfio | 76.0 mg/1.9mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug. 15, 2023 | In Use | |
00069-2522-02 | 00069-2522 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug. 15, 2023 | In Use | |
67386-0411-51 | 67386-0411 | Asparaginase (E. coli) | Elspar | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular | Jan. 10, 1978 | July 18, 2013 | No Longer Used | |
72187-0401-01 | 72187-0401 | Tagraxofusp | Elzonris | 1000.0 ug/mL | Immunotherapy | Fusion Protein | IL3/ CD123 | Intravenous | Jan. 18, 2019 | In Use | |
00013-0132-02 | 00013-0132 | Estramustine Phosphate Sodium | Emcyt | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Jan. 1, 1992 | Sept. 30, 2024 | In Use |
00006-0462-01 | 00006-0462 | Aprepitant | Emend | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0462-06 | 00006-0462 | Aprepitant | Emend | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | May 31, 2020 | In Use |
00006-0462-30 | 00006-0462 | Aprepitant | Emend | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | July 14, 2010 | In Use |
00006-3862-03 | 00006-3862 | Aprepitant | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | March 26, 2003 | In Use | |||
00006-3862-13 | 00006-3862 | Aprepitant | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | March 26, 2003 | In Use | |||
54868-5325-00 | 54868-5325 | Aprepitant | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | June 24, 2005 | In Use | |||
00006-3941-01 | 00006-3941 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov. 19, 2010 | In Use | |
00006-3941-32 | 00006-3941 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov. 12, 2010 | In Use | |
00006-0464-01 | 00006-0464 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0464-05 | 00006-0464 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | Dec. 31, 2020 | In Use |
00006-0464-10 | 00006-0464 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | Dec. 31, 2020 | In Use |
00006-0461-01 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0461-02 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0461-06 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | April 30, 2020 | In Use |
00006-0461-12 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0461-30 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | July 14, 2010 | In Use |
00006-3884-01 | 00006-3884 | Fosaprepitant Dimeglumine | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | July 8, 2010 | July 31, 2012 | No Longer Used | ||
00006-3884-32 | 00006-3884 | Fosaprepitant Dimeglumine | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Jan. 25, 2008 | July 31, 2012 | No Longer Used | ||
00006-3066-01 | 00006-3066 | Aprepitant | Emend | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec. 17, 2015 | In Use | |
00006-3066-03 | 00006-3066 | Aprepitant | Emend | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec. 17, 2015 | In Use | |
42254-0160-01 | 42254-0160 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
54868-5231-01 | 54868-5231 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | June 29, 2005 | In Use | |
54868-5231-02 | 54868-5231 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | June 29, 2005 | In Use | |
54868-5231-03 | 54868-5231 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | June 29, 2005 | In Use | |
00006-3061-00 | 00006-3061 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 3, 2017 | In Use | |
00006-3061-01 | 00006-3061 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 3, 2017 | In Use | |
00006-3061-04 | 00006-3061 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 3, 2017 | May 25, 2021 | In Use |
00006-3061-02 | 00006-3061 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 3, 2017 | May 16, 2021 | In Use |
00003-2291-11 | 00003-2291 | Elotuzumab | Empliciti | 300.0 mg/1 | Immunotherapy | Monoclonal Antibody | SLAMF7 | Intravenous | Nov. 30, 2015 | In Use | |
00003-4522-11 | 00003-4522 | Elotuzumab | Empliciti | 400.0 mg/1 | Immunotherapy | Monoclonal Antibody | SLAMF7 | Intravenous | Nov. 30, 2015 | In Use | |
65597-0406-01 | 65597-0406 | fam-trastuzumab deruxtecan-nxki | Enhertu | 100.0 mg/5mL | Immunotherapy | Drug Antibody Conjugate | Topoisomerase I Inhibitor | Intravenous | Dec. 20, 2019 | In Use | |
00143-9202-01 | 00143-9202 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 7, 2007 | In Use | |
00143-9203-01 | 00143-9203 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 7, 2007 | In Use | |
00703-3067-11 | 00703-3067 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 50.0 mg/25mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 9, 2007 | Nov. 30, 2017 | No Longer Used |
00703-3069-11 | 00703-3069 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 200.0 mg/100mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 9, 2007 | March 31, 2017 | No Longer Used |
59762-5091-01 | 59762-5091 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 15, 1999 | In Use | |
59762-5093-01 | 59762-5093 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 15, 1999 | In Use | |
45963-0608-60 | 45963-0608 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Nov. 28, 2011 | Oct. 31, 2020 | No Longer Used |
45963-0608-68 | 45963-0608 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Nov. 28, 2011 | June 30, 2021 | No Longer Used |
66758-0042-01 | 66758-0042 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec. 22, 2009 | May 31, 2014 | In Use |
66758-0042-02 | 66758-0042 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec. 22, 2009 | May 31, 2014 | In Use |
53150-0247-01 | 53150-0247 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 200.0 mg/100mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | July 31, 2013 | Dec. 31, 2017 | No Longer Used |
53150-0250-01 | 53150-0250 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 50.0 mg/25mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | July 31, 2013 | Dec. 31, 2017 | No Longer Used |
61703-0359-59 | 61703-0359 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 8, 2007 | Aug. 31, 2016 | No Longer Used |
61703-0359-93 | 61703-0359 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 8, 2007 | Aug. 31, 2016 | No Longer Used |
67457-0357-25 | 67457-0357 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 50.0 mg/25mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | July 31, 2013 | April 30, 2015 | No Longer Used |
67457-0358-10 | 67457-0358 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 200.0 mg/100mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | July 31, 2013 | April 30, 2015 | No Longer Used |
00115-1675-72 | 00115-1675 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 21, 2016 | April 3, 2019 | In Use |
00115-1675-73 | 00115-1675 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sept. 21, 2016 | Oct. 31, 2018 | In Use |
25021-0203-25 | 25021-0203 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 31, 2014 | Sept. 30, 2019 | No Longer Used |
25021-0203-51 | 25021-0203 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug. 31, 2014 | Sept. 30, 2019 | No Longer Used |
59923-0701-00 | 59923-0701 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 19, 2014 | In Use | |
59923-0701-25 | 59923-0701 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 19, 2014 | In Use | |
55513-0823-01 | 55513-0823 | Epoetin alfa | Epogen | Ancillary Therapy | Erythropoiesis-Stimulating Agent | March 3, 1997 | July 31, 2010 | No Longer Used | |||
55513-0823-10 | 55513-0823 | Epoetin alfa | Epogen | Ancillary Therapy | Erythropoiesis-Stimulating Agent | March 3, 1997 | July 31, 2010 | No Longer Used |
Found 10,000 results in 7 milliseconds — Export these results